Ryotaro Morinaga

Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation

Ryotaro Morinaga, Isamu Okamoto, Kazuyuki Furuta et al. · Lung Cancer · 2007 · 113 citations

Sequential Occurrence, Non-small Cell, Tumor Heterogeneity +11

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Isamu Okamoto, Hiroyasu Kaneda, Taroh Satoh et al. · Molecular Cancer Therapeutics · 2010 · 94 citations · Full text

Oncology, Medicine, Malignant Blood Disorder +14

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non–small cell lung cancer harboring <i>EGFR</i> mutations

Kentaro Tanaka, Kaname Nosaki, Kohei Otsubo et al. · Oncotarget · 2017 · 75 citations · Full text

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

Eiji Iwama, Yasushi Goto, Haruyasu Murakami et al. · Journal of Thoracic Oncology · 2017 · 54 citations

Oncology, Cancer Management, Pathology +8

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

Daichi Fujimoto, Satoru Miura, Kenichi Yoshimura et al. · JTO Clinical and Research Reports · 2021 · 48 citations · Full text

Oncology, Medicine, Pembrolizumab Plus Chemotherapy +7